BioLineRx announced that the U.S. FDA has approved APHEXDA in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA is administered by injection, for subcutaneous use.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLRX:
- Biotech Alert: Searches spiking for these stocks today
- BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
- Options Volatility and Implied Earnings Moves Today, August 30, 2023
- Options Volatility and Implied Earnings Moves This Week, August 28 – August 31, 2023
- BLRX Earnings this Week: How Will it Perform?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue